Introduction
============

High-grade gliomas are generally aggressive tumors with poor prognosis \[[@B1]\]. They tend to recur locally \[[@B2]\] and rarely spread beyond the confines of the central nervous system. Therefore, local control is considered the primary determinant of overall survival. Treatment routinely consists of maximum safe surgery followed by postoperative conventionally fractionated radiation therapy plus or minus chemotherapy \[[@B3]-[@B6]\]. With standard therapy, including Temozomide, the 2 year overall survival estimate for glioblastoma multiforme (GBM) is an improved but yet still disappointing 27% \[[@B4]\]. Anaplastic glioma outcomes are considerably better with a 4 year overall survival estimate of approximately 50% \[[@B5],[@B6]\]. Current practice guidelines recommend treating high-grade gliomas with conventionally fractionated (1.8 - 2.0 Gy) partial brain irradiation over an approximately 6 week period \[[@B7]\]. The gross tumor volume (GTV) is targeted with large margins (2-3 cm) too addresses deep subclinical brain infiltration \[[@B8]\]. Radiosurgy with or without conventional irradiation is not recommended at this time given the poor tolerance of the normal brain to hypofractionation \[[@B9]\] and disappointing published treatment outcomes \[[@B10]-[@B13]\].

Presently, it is our clinical practice to treat high-grade glioma patients with maximum safe surgery followed by 6 weeks of chemoradiation (60 Gy partial brain irradiation in 2 Gy fractions with concurrent and adjuvant Temozolomide). It has been generally feasible with conventional radiation technique to deliver such \"full dose\" treatment while respecting institutional peritumoral critical structure maximum point dose tolerances (Table [1](#T1){ref-type="table"}). However, for some deep seated tumors, typically involving the temporal and frontal lobes, such treatment is often not feasible with conventional treatment inaccuracies approaching 5 mm in the best hands \[[@B14],[@B15]\]. Historically, the total radiation dose has been lowered in such cases to protect normal tissue function with the understanding that such treatment modifications could adversely affect overall survival \[[@B16]\]. With recent Temozolomide-related improvements in high-grade glioma survival \[[@B4]\], it is now more likely than ever that suboptimal radiation treatment will result in either a decrement in overall survival or an increase in late radiation toxicity.

###### 

Cumulative Radiation Maximum Point Dose Limits

  Critical Structure   Maximum Point Dose Limit (total for 30 fractions)
  -------------------- ---------------------------------------------------
  Lens                 10 Gy
                       
  Retina               50 Gy
                       
  Optic Nerve          55 Gy
                       
  Optic Chiasm         55 Gy
                       
  *Brainstem*          55 Gy

The CyberKnife^®^, a commercially available frameless image-guided radiosurgery system (Accuray, Sunnyvale, CA), was installed at Georgetown University Hospital in late 2001. Standard components include a light weight linear accelerator, a robotic manipulator and an automated x-ray image-guided computer targeting system. Generally, the treatment planning system with input from the user selects hundreds of small non-isocentric circular radiation beams to deliver a highly conformal radiation treatment with steep dose gradients to a defined target in order to spare normal tissues \[[@B17],[@B18]\]. Subsequently, the automated robotic manipulator directed by the frequently updated x-ray targeting system\'s knowledge of the patient\'s unique cranial anatomy efficiently delivers the selected radiation beams with submilimeter accuracy. We report the safety and efficacy of using the highly conformal and accurate CyberKnife radiosurgery system to enhance the final week of conventional radiotherapy in 24 patients with high-grade gliomas in close proximity to critical structures.

Patients and Methods
====================

Patient Population
------------------

Patients with newly diagnosed resected unifocal high-grade gliomas (WHO Grade III and VI) in close proximity (\<1 cm) to critical structures (Table [2](#T2){ref-type="table"}) were evaluated. All patients were in RPA class 1 to 4 \[[@B19],[@B20]\]. Magnetic resonance imaging (MRI) was completed preoperatively and postoperatively. The Georgetown University Hospital institutional review board approved this study and all participants provided informed written consent.

###### 

Patient Characteristics

  Patient   Histology                      Resection   Chemotherapy              Lobe          RPA   Age   Sex      Deficit
  --------- ------------------------------ ----------- ------------------------- ------------- ----- ----- -------- ---------
  1         Glioblastoma multiforme        Total       Concurrent and Adjuvant   Frontal-L     4     60    Male     No
                                                                                                                    
  2         Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Frontal-L     3     44    Female   No
                                                                                                                    
  3         Anaplastic oligodendroglioma   Total       Adjuvant                  Frontal-L     1     27    Male     No
                                                                                                                    
  4         Anaplastic oligoastrocytoma    Total       None                      Frontal-R     1     33    Male     No
                                                                                                                    
  5         Anaplastic astrocytoma         Total       Adjuvant                  Frontal-R     1     42    Female   No
                                                                                                                    
  6         Anaplastic oligodendroglioma   Total       Concurrent and Adjuvant   Frontal-R     1     42    Male     No
                                                                                                                    
  7         Anaplastic astrocytoma         Total       Adjuvant                  Frontal-R     1     39    Female   No
                                                                                                                    
  8         Anaplastic astrocytoma         Subtotal    Concurrent and Adjuvant   Frontal-R     2     62    Female   Yes
                                                                                                                    
  9         Glioblastoma multiforme        Total       Concurrent and Adjuvant   Occipital-R   4     70    Female   No
                                                                                                                    
  10        Anaplastic oligoastrocytoma    Total       Adjuvant                  Parietal-R    1     48    Male     No
                                                                                                                    
  11        Anaplastic oligoastrocytoma    Total       Adjuvant                  Temporal-L    1     42    Male     No
                                                                                                                    
  12        Glioblastoma multiforme        Total       Concurrent and Adjuvant   Temporal-L    4     72    Female   No
                                                                                                                    
  13        Anaplastic astrocytoma         Subtotal    Concurrent and Adjuvant   Temporal-L    1     28    Female   No
                                                                                                                    
  14        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-L    4     51    Female   No
                                                                                                                    
  15        Anaplastic astrocytoma         Total       Concurrent and Adjuvant   Temporal-R    2     66    Female   No
                                                                                                                    
  16        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-R    4     63    Female   No
                                                                                                                    
  17        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-R    4     59    Female   No
                                                                                                                    
  18        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-R    4     56    Male     No
                                                                                                                    
  19        Anaplastic astrocytoma         Subtotal    Concurrent and Adjuvant   Temporal-R    2     67    Male     No
                                                                                                                    
  20        Glioblastoma multiforme        Total       Concurrent and Adjuvant   Temporal-R    4     69    Male     No
                                                                                                                    
  21        Anaplastic astrocytoma         Total       Concurrent and Adjuvant   Temporal-R    1     16    Male     No
                                                                                                                    
  22        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-R    4     55    Male     No
                                                                                                                    
  23        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-R    4     57    Male     No
                                                                                                                    
  24        Glioblastoma multiforme        Subtotal    Concurrent and Adjuvant   Temporal-R    4     65    Female   No

Surgery
-------

The extent of surgical resection was documented as total tumor resection or subtotal tumor resection following review of operative reports and post operative MRI imaging (Table [2](#T2){ref-type="table"}). Salvage surgery was routinely recommended for patients with good performance status and evidence of recurrence or radiation necrosis based on imaging studies.

Conventional Radiation Treatment
--------------------------------

Patients were placed in the supine treatment position with their heads resting on a standard support. A custom thermoplastic mask was crafted. Thin-sliced (1.25 mm) high-resolution CT images were obtained through the cranium for conventional and CyberKnife treatment planning. Treatment planning MRI imaging was completed selectively to enhance target and critical structure delineation when clinically indicated. Target volumes and critical structures were contoured by team neurosurgeons. Treatment volumes were generous including the contrast enhancing tumor volume when present and the surgical defect with a 3 cm margin. Critical structures in close proximity to the target volume were not excluded from the treatment volume during conventional radiation treatment. Forty to 50.4 Gy was delivered in 1.8 to 2.0 Gy fractions 5 days a week for a total of 4 to 5 1/2 weeks. Treatment was delivered using linear accelerators with nominal energies ≥ 6 MV. Intensity modulated radiation therapy (IMRT) technique was not permitted.

CyberKnife Treatment
--------------------

Following the completion of conventional radiation therapy, CyberKnife treatment was completed without a planned treatment break (Figure [1](#F1){ref-type="fig"}). The technical aspects of CyberKnife^®^radiosurgical system for cranial tumors have been described in detail \[[@B17],[@B18]\]. The treatment volume for the radiosurgical boost included the contrast-enhancing lesion and the resection cavity as defined by the patient\'s neurosurgeon plus a 1 cm margin when clinically indicated (Figure [1A, B](#F1){ref-type="fig"}). Due to the submillimeter precision of CyberKnife treatment, no additional margin was added to correct for set-up inaccuracy. The treating neurosurgeon and radiation oncologist in consultation determined the prescription isodose line (Figure [1C](#F1){ref-type="fig"}). Twelve circular collimator ranging in diameter form 5 to 60 mm are available with the CyberKnife^®^radiosurgical system. An inverse planning method with non-isocenteric technique was used. The treating physician and physicist input the specific treatment criteria, limiting the maximum dose to critical structures (Figure [1C](#F1){ref-type="fig"}). The planning software calculated the optimal solution for treatment. The DVH of each plan was evaluated until an acceptable plan was generated. Strict adherence to critical normal structure dose constraints was maintained (Table [1](#T1){ref-type="table"}).

![**(A) Axial T1-weighted post contrast MRI illustrating a right-sided temporal lobe high-grade glioma resection cavity bordering the right optic nerve, optic chiasm and brainstem**. **(B)**Planning Axial CT image. The radiosurgical planning treatment volume is contoured in red and critical structures are contoured in green. **(C)**Planning Axial CT illustrating the prescription isodose line in yellow and the 50% isodose line in blue.](1756-8722-3-22-1){#F1}

CyberKnife Treatment Planning Parameters
----------------------------------------

### Treatment Volume

Treatment volume was defined as the volume contoured on the planning CT scan by the treating neurosurgeon plus a 1 cm margin when clinically indicated. In this study, there was no limit set on the treatable target volumes.

### Homogeneity Index

The homogeneity index (HI) describes the uniformity of dose within a treated target volume, and is directly calculated from the prescription isodose line chosen to cover the margin of the tumor:

HI = Maximum dose/prescription dose

### New Conformity Index

The new conformity index (NCI) as formulated by Paddick \[[@B21]\], and modified by Nakamura \[[@B22]\] describes the degree to which the prescribed isodose volume conforms to the shape and size of the target volume. It also takes into account avoidance of surrounding normal tissue.

### Percent Target Coverage

PTC = The percentage of the target volume covered by the prescription isodose line.

CyberKnife Treatment Delivery
-----------------------------

Image-guided radiosurgery was employed to eliminate the need for stereotactic frame fixation. Using computed tomography planning, target volume locations were related to cranial landmarks. With the assumption that the target position is fixed within the cranium, cranial tracking allows for anatomy based tracking relatively independent of patient\'s daily setup. Position verification was validated every third beam during treatment using paired, orthogonal, x-ray images \[[@B23],[@B24]\].

Chemotherapy
------------

Patients received concurrent and/or adjuvant chemotherapy at the discretion of their medical oncologist. Typically, patients were administered Temozolomide with concurrent radiation at a dose of 75 mg/m2/d, given 7 d/wk from the first day of conventional irradiation until the last day of CyberKnife treatment. After a 4-week break, patients generally received 6 cycles or more of adjuvant Temozolomide on a 5-day schedule of 150 to 200 mg per square meter every 28 days.

Clinical Assessment and Follow-up
---------------------------------

Clinical evaluation and MRI imaging were performed at 3-6 month intervals following CyberKnife treatment for 5 years. Evaluation frequency beyond 5 years was determined by the medical oncologist. Throughout the follow-up period, a multidisciplinary team of neurosurgeons, radiation oncologists, medical oncologist and radiologists reviewed outcomes at a weekly central nervous system tumor board. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 \[[@B25]\]

Statistical Analysis
--------------------

The follow-up duration was defined as the time from the date of surgery to the last date of follow-up for surviving patients or to the date of death. Actuarial survival and local control was calculated using the Kaplan-Meier method.

Results
=======

Patient and Tumor Characteristics
---------------------------------

Twenty four consecutive eligible patients were treated over a seven year period extending from January 2002 to January 2009 (Table [2](#T2){ref-type="table"}) and were followed for a minimum of 12 months or until death. The mean age of the group was 52 years (range, 27-72). Tumors were evenly distributed between anaplastic glioma (WHO III) and glioblastoma multiformi (WHO IV). Ninety-two percent of the tumors involved the temporal and/or frontal lobes.

Treatment Characteristics
-------------------------

Thirteen tumors were completely resected; eleven were subtotaly resected. All patients received conventional radiation therapy following tumor resection, with a median dose of 50 Gy (range: 40 - 50.4 Gy). Upon completion of conventional treatment, an additional dose of 10 Gy was delivered in five successive 2 Gy daily fractions utilizing the CyberKnife^®^image-guided radiosurgical system. Treatment plans were composed of hundreds of pencil beams shaped using a single circular collimator to generate highly conformal plans (mean new conformity index of 1.62, Table [3](#T3){ref-type="table"}). Selected plans were inhomogeneous by design (mean homogeneity index of 1.38, Table [3](#T3){ref-type="table"}) to minimize dose to adjacent critical structures. Radiation was delivered to a mean prescription isodose line of 73% (Table [3](#T3){ref-type="table"}) in 5 approximately 1 hour long treatments. On average, 173 beams were employed to treat the mean prescription volume of 174 cc with a mean percent target coverage of 94%. An average of 58 verification images were taken during each treatment to account for intrafraction patient motion. Twenty-one patients received concurrent and/or adjuvant Temozolmide. Two patients received adjuvant procarbazine, lomustine, vincristine (PCV) alone and one patient declined chemotherapy.

###### 

Treatment Characteristics

  Characteristic                                
  --------------------------------------------- ------
  Homogeneity Index                             
   Min                                          1.22
   Max                                          1.67
   Mean                                         1.38
   Median                                       1.43
                                                
  New Conformality Index                        
   Min                                          1.20
   Max                                          1.84
   Mean                                         1.62
   Median                                       1.54
                                                
  Prescription Isodose Line (%)                 
   Min                                          60
   Max                                          80
   Mean                                         73
   Median                                       70
                                                
  Treatment Volume (cc)                         
   Min                                          13
   Max                                          550
   Mean                                         174
   Median                                       95
                                                
  Percent Tumor Coverage                        
   Min                                          79
   Max                                          99
   Mean                                         94
   Median                                       96
                                                
  Number of Radiation Beams Utilized            
   Min                                          87
   Max                                          288
   Mean                                         173
   Median                                       151
                                                
  Number of Verification Images Per Treatment   
   Min                                          29
   Max                                          96
   Mean                                         58
   Median                                       50

Outcomes
--------

The median follow-up was 23 months (range, 13-60 months) for glioblastoma multiforme patients and 63 months (range, 21-85 months) for anaplastic glioma patients (Table [4](#T4){ref-type="table"}). No patients were lost to follow-up. Nine of twelve GBM patients (75%) experienced local progression, seven of which died during the follow-up period. Six of the twelve anaplastic patients (50%) experienced local progression, four deaths occurred during the clinical follow-up period. The median time to local progression was 16 months for the glioblastoma multiformi group and 33 months for the anaplastic glioma group. The median survival was 18 months for the glioblastoma multiforme group with a two-year survival rate of 37%. The median survival was not reached for the anaplastic glioma group and the 4-year survival rate was 71% (Figure [2](#F2){ref-type="fig"}). Of those who died in the glioblastoma multiforme group, 7 (89%) had local disease progression and of those who died in the anaplastic glioma group 4 (100%) had local disease progression (Figure [2](#F2){ref-type="fig"}). The median time to death was 18 months for the glioblastoma multiformi group and 36 months for the anaplastic glioma group. There were no severe (≥ grade 3) radiation complications per the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 with this conservative treatment strategy.

###### 

Group Clinical Outcomes

                                       GBM   Anaplastic
  ------------------------------------ ----- ------------
  Follow-up (Months)                         
   Min                                 13    21
   Max                                 60    85
   Mean                                22    58
   Median                              23    63
  Time to local progression (Months)         
   Min                                 9     9
   Max                                 60    48
   Mean                                20    29
   Median                              16    33
  Survival (%)                               
   2 Year                              37    91
   4 Year                              19    71
  Time to Death (Months)                     
   Min                                 9     21
   Max                                 60    60
   Mean                                22    38
   Median                              18    36
   Complications (≥ Grade 3)           0     0

![**Kaplan-Meier plot of overall survival**.](1756-8722-3-22-2){#F2}

Salvage Therapy
---------------

Ultimately, 16 patients experienced local progression during follow-up (Table [5](#T5){ref-type="table"}). Salvage surgery was clinically indicated and pursued in 10 patients, 4 with glioblastoma multiforme and 6 with anaplastic glioma. Each surgery confirmed recurrent glioma with treatment effect. Necrosis was not observed in the absence of tumor progression. Five patients completed salvage chemotherapy, 3 from the glioblastoma multiformi group and 2 from the anaplastic glioma group. A single glioblastoma multiforme patient survived 10 weeks following salvage CyberKnife radiosurgery.

###### 

Individual Clinical Outcomes

  Patient   Time to Progression (months)   Vital Status   Time to Death (months)   Clinical Follow-up (months)   Salvage Radiation   Salvage Chemotherapy   Salvage Surgery
  --------- ------------------------------ -------------- ------------------------ ----------------------------- ------------------- ---------------------- -----------------
  1         18                             Dead           30                       n/a                           No                  No                     No
                                                                                                                                                            
  2         18                             Dead           21                       n/a                           No                  No                     Yes
                                                                                                                                                            
  3         n/a                            Alive          n/a                      73                            No                  No                     No
                                                                                                                                                            
  4         36                             Dead           36                       n/a                           No                  No                     Yes
                                                                                                                                                            
  5         n/a                            Alive          n/a                      70                            No                  No                     No
                                                                                                                                                            
  6         n/a                            Alive          n/a                      85                            No                  No                     No
                                                                                                                                                            
  7         n/a                            Alive          n/a                      71                            No                  No                     No
                                                                                                                                                            
  8         15                             Dead           21                       n/a                           No                  No                     Yes
                                                                                                                                                            
  9         9                              Dead           12                       n/a                           Yes                 No                     No
                                                                                                                                                            
  10        30                             Dead           36                       n/a                           No                  Yes                    Yes
                                                                                                                                                            
  11        48                             Dead           60                       n/a                           No                  No                     Yes
                                                                                                                                                            
  12        60                             Dead           60                       n/a                           No                  Yes                    No
                                                                                                                                                            
  13        36                             Alive          n/a                      56                            No                  No                     Yes
                                                                                                                                                            
  14        9                              Dead           12                       n/a                           No                  Yes                    Yes
                                                                                                                                                            
  15        n/a                            Alive          n/a                      53                            No                  No                     No
                                                                                                                                                            
  16        9                              Dead           18                       n/a                           No                  No                     Yes
                                                                                                                                                            
  17        16                             Dead           18                       n/a                           No                  No                     No
                                                                                                                                                            
  18        30                             Alive          n/a                      30                            No                  No                     Yes
                                                                                                                                                            
  19        n/a                            Alive          n/a                      32                            No                  No                     No
                                                                                                                                                            
  20        12                             Dead           18                       n/a                           No                  No                     No
                                                                                                                                                            
  21        9                              Alive          n/a                      21                            No                  Yes                    Yes
                                                                                                                                                            
  22        16                             Alive          n/a                      23                            No                  Yes                    No
                                                                                                                                                            
  23        n/a                            Dead           9                        n/a                           No                  No                     No
                                                                                                                                                            
  24        n/a                            Alive          n/a                      13                            No                  No                     No

Discussion
==========

High grade gliomas adjacent to critical structures are difficult to treat with conventional radiation therapy technique alone \[[@B15]\]. When irradiating such tumors strict adherence to critical normal structure dose constraints may spare tumors full dose irradiation, potentially resulting in premature local failure and death. Conversely, delivering high doses of radiation immediately adjacent to critical structures without strict limitation increases the risk of late radiation induced complications \[[@B9]\]. Temozolomide-related improvements in high-grade glioma survival have amplified this risk. The number of patients with glioblastoma multiforme surviving past two years is increasing (\> 20%) \[[@B4]\] and more than half of patients with anaplastic gliomas are expected to live longer than 4 years. \[[@B5],[@B6]\] These statistics justify current attempts to limit late radiation morbidity. While 3D-conformal radiation therapy \[[@B26]\] and IMRT \[[@B27]\] treatment plans appear to adequately treat the target volume and spare adjacent critical structure, documented set-up inaccuracies and uncorrected intrafraction patient motion increase the risk of potentially costly radiation misadministration.

In this study, we utilized the highly conformal and accurate fractionated CyberKnife radiotherapy to enhance conventional radiotherapy and investigated the safety and efficacy of this technique. The CyberKnife^®^radiosurgical system has several advantages over conventional radiation delivery systems. Since hundreds of non-isocentric treatment beams are available, the CyberKnife is capable of delivering a highly conformal treatment \[[@B17],[@B18]\]. Cranial tracking, using skeletal anatomy to position the radiation beam, is as precise as frame-based approaches (accuracy \<1 mm) \[[@B28]-[@B31]\]. Furthermore, by rendering invasive head frames unnecessary, the CyberKnife approach facilitates fractionate treatment while maintaining radiosurgical accuracy.

This is the first study to evaluates CyberKnife enhanced conventionally fractionated radiation therapy and chemotherapy for high-grade gliomas. Twenty-four patients were treated with encouraging 2 year and 4 year overall survival rates of 37% and 71% for the glioblastoma multiforme and anaplastic glioma cohorts, respectively. There were no severe late toxicities attributed to this technique using conventional total radiation doses of approximately 60 Gy. Our results demonstrate the feasibility, tolerability and efficacy of delivering CyberKnife enhanced conventionally fractionated radiation therapy and chemotherapy. Unfortunately, local progression remains the predominant pattern of failure for these patients despite optimal radiation treatment and chemotherapy (Figure [3](#F3){ref-type="fig"}) as confirmed by our salvage surgery analysis (Table [5](#T5){ref-type="table"}). Nonetheless, image-guided radiation remains a useful tool to optimize available treatment for patients with tumors in close proximity to critical structures.

![**Kaplan-Meier plot of local control**.](1756-8722-3-22-3){#F3}
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